Compare Incyte Corporation (INCY) vs Norfolk Southern Corporation (NSC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Norfolk Southern Corporation — how do they compare? Incyte Corporation trades at $113.06 (market cap $22.85B), while Norfolk Southern Corporation trades at $316.89 (market cap $71.20B). The key difference: Norfolk Southern Corporation is far larger — about 3.1× Incyte Corporation's market cap, and Norfolk Southern Corporation pays a 1.7% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and Norfolk Southern Corporation for 33 Days on average.
| INCY | NSC | |
|---|---|---|
Market Cap | $22.85B | $71.20B |
Volume | 1,927,029 | 555,248 |
Sector | Health | Industrials |
52-Week High | $129.93 | $352.98 |
52-Week Low | $83.80 | $278.19 |
Typical Hold Time | 33 Days | 33 Days |
Enterprise Value | $18.35B | $86.75B |
Dividend Yield | — | 1.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $113.44, up 0.63% with a bullish technical signal despite mixed moving averages. The company shows strong fundamentals with 2025 revenue of $5.14B, net income of $1.29B, and impressive profitability margins (gross margin 92.62%, net margin 27.71%). Recent FDA approval for Atebrioz and pipeline expansion signal growth beyond JAKAFI. Valuation appears reasonable with P/E of 14.36 and P/S of 3.98.
Outlook remains positive with analyst consensus target of $132.43 (16.7% upside) and 52% buy ratings. Key opportunities include pipeline diversification and $4B sales target, while risks involve JAKAFI patent expiration post-2029 and competitive pressures. Strong cash flow generation ($1.41B operating CF) supports continued R&D investment.
Norfolk Southern (NSC) trades at $317.14, up 1.26% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $361.86. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected soon. Strong profitability is evidenced by a 21.02% net income margin and 16.97% ROE, while news highlights significant institutional investment and progress on the proposed merger with Union Pacific.
The outlook is positive, supported by earnings momentum and potential merger benefits, but risks include integration challenges, fuel cost pressures noted in recent news, and a relatively high P/E ratio of 27.05. The stock offers a dividend yield and growth potential, contingent on successful execution of strategic initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Norfolk Southern Corporation
Norfolk Southern Corporation is a major North American railroad company operating one of the largest freight rail networks in the eastern United States. The company transports a diverse range of commodities, including coal, intermodal containers, and various industrial products. NSC is a critical link in the nation's supply chain, providing efficient, long-haul transportation services to and from ports and industrial centers.
Read more on NSC →
